Status and phase
Conditions
Treatments
About
The GI-5005 therapeutic vaccine in combination with standard of care or standard of care alone will be injected under the skin of HCV subjects. Patients will be monitored for safety, immune responses and any therapeutic benefits related to the injections including EVR, ETR, and SVR.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Non-Responders
Naive
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
140 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal